Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. - Chohan KL; Gensini L; Seif S; Sun X; Feng L; Becnel MR; Gaballa MM; Lee HC; Pasvolsky O; Patel KK; Ye JC; Weber DM; et al. (Blood cancer journal, 2025)